BioMarin Completes Acquisition of Amicus Therapeutics
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said that it completed the previously announced agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The acquisition will strengthen BioMarin’s commercial portfolio, adding two new treatments to the company’s existing portfolio of medicines that target lysosomal […]
BioMarin Completes Acquisition of Amicus Therapeutics Read More »
